1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1.Drivers
3.2.2.Restraints
3.2.3.Opportunities
3.2.4.Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for China Biological Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in China Biological Drugs Market
4. China Biological Drugs Market by
Product Type
4.1. Therapeutic Protein
4.1.1. Enbrel
4.1.2. Lantus
4.1.3. Neulasta
4.1.4. Avones
4.1.5. Novolog
4.1.6. Rebif
4.1.7. Humalog
4.1.8. Other Therapeutic Protein
4.2. Monoclonal Antibody
4.2.1. Humira
4.2.2. Remicade
4.2.3. Rituxan
4.2.4. Avastin
4.2.5. Herceptin
4.2.6. Lucentis
4.2.7. Other Monoclonal Antibodies
4.3. Vaccines
4.3.1. Prevnar 13
4.3.2. Gardasil
4.3.3. Fluzone
4.3.4. Varivax
4.3.5. Cervarix
4.3.6. Other Vaccines
5. Company Profiles
5.1. Company 1
5.2. Company 2
5.3. Company 3
5.4. Company 4
5.5. Company 5
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1.Drivers
3.2.2.Restraints
3.2.3.Opportunities
3.2.4.Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for China Biological Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in China Biological Drugs Market
4. China Biological Drugs Market by
Product Type
4.1. Therapeutic Protein
4.1.1. Enbrel
4.1.2. Lantus
4.1.3. Neulasta
4.1.4. Avones
4.1.5. Novolog
4.1.6. Rebif
4.1.7. Humalog
4.1.8. Other Therapeutic Protein
4.2. Monoclonal Antibody
4.2.1. Humira
4.2.2. Remicade
4.2.3. Rituxan
4.2.4. Avastin
4.2.5. Herceptin
4.2.6. Lucentis
4.2.7. Other Monoclonal Antibodies
4.3. Vaccines
4.3.1. Prevnar 13
4.3.2. Gardasil
4.3.3. Fluzone
4.3.4. Varivax
4.3.5. Cervarix
4.3.6. Other Vaccines
5. Company Profiles
5.1. Company 1
5.2. Company 2
5.3. Company 3
5.4. Company 4
5.5. Company 5